Topping tamoxifen as 1st-line Rx for postmenopausal breast Ca

Article

Aromatase inhibitors should replace tamoxifen as the first choice for preventing recurrence of breast cancer in postmenopausal women with localized hormone receptor-positive disease, according to this large-scale study.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.